Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases
Key Highlights
- ➤$330 million upfront payment for three pre-IND in vivo CAR-T programs
- ➤Up to $2.3 billion in milestone payments plus royalties on net sales
- ➤Pfizer (PFE) gains exclusive rights outside Greater China for autoimmune CAR-T programs
- ➤Pfizer will lead clinical development and manufacture initial trial drug product in U.S.
- ➤Pfizer receives in vivo CAR-T rights spanning inflammation, immunology and oncology
Expert Statements
Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer
“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches.”
Rongkuan Hu, Ph.D., Chief Executive Officer, Starna Therapeutics
“Our vision at Starna is to unlock the potential of RNA medicines to transform patient care. We believe our proprietary targeted LNP delivery platform and RNA technology provide a strong foundation for advancing in vivo CAR-T therapies. We are excited to join forces with Pfizer, a global leader in drug development, to bring transformative therapies to patients worldwide.”
Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases
Pfizer Inc. (NYSE: PFE) today announced that it entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases. Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in Greater China.
Get started
Create a free account to read the full story.
